Biopharmaceuticals Market: How Is the Commercial Biosimilar Erosion...

adicionou um novo artigo Wellness

2026-06-05 09:58:31 -

Biopharmaceuticals Market: How Is the Commercial Biosimilar Erosion of Blockbuster Biopharmaceutical Revenue Creating Strategic Portfolio Repositioning?

Blockbuster biopharmaceutical patent cliff commercial impact — the commercial revenue erosion that biosimilar competition creates when major biopharmaceutical patents expire — exemplified by Humira's (adalimumab) commercial revenue decline from USD 21.2 billion peak to dramatically lower post-biosimilar launch levels as Amjevita, Hadlima, Cyltezo, Hyrimoz, and multiple additional...

0 Comentários 0 Compartilhamentos 36 Visualizações 0 Anterior